Sutro Biopharma
Sutro Biopharma
Agent36Agent Readiness: 36/100. Below median. Measured by StartupHub.ai. Median 41.Clinical-stage biopharma developing precisely designed cancer therapeutics using a proprietary cell-free protein synthesis platform.
About
Sutro Biopharma is a clinical-stage biotechnology company focused on discovering, developing, and manufacturing precisely designed cancer therapeutics. They leverage a proprietary cell-free protein synthesis platform, XpressCF®, to create novel antibody-drug conjugates (ADCs) and other protein-based therapeutics.
Key facts
At-a-glance profile data
- Website
- sutrobio.com
- Headquarters
- South San Francisco, United States
- Founded
- 2003
- Total funding
- $270M (Public Offering)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 9 Feb 2026 | Public Offering | $110M | - |
| 2 Apr 2024 | Public Offering | $75M | - |
| 26 Jul 2018 | Series E | $85M | Samsara BioCapital, Citadel |
Tech stack
Detected on sutrobio.com, last scanned 19 Sept 2026. Run your own scan
- Compliance
- GDPR
- Frontend
- jQuery
- Auth
- Entra App Proxy
- Analytics
- Google Analytics 4, Segment
- CMS / Builders
- WordPress
- Hosting
- AWS
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has Sutro Biopharma raised?
Sutro Biopharma has raised a total of $270M in funding. The most recent round on record is Public Offering.